Chelsea Sierra Voss bought $5,522 of QCLS
director at MyMD Pharmaceuticals, Inc.. 1,753 shares at an average of $3.15, traded Mar 30, 2026, filed May 14, 2026.
Score components
- +15RoleDirector
- 0Trade size$6k at market
- 0Relative to holdingsHoldings up 2.9%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001493152-26-023217, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 30, 2026 | POpen-market purchase Common stockindirect: By Roth IRA | +1,753 | $3.15 | $5,522 | 61,555 | May 14, 2026 |
Related signals
Other insiders at MyMD Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 33Weak | QCLSbuy MyMD Pharmaceuticals, Inc. | Paul Rivard EVP of Operations, GC | $15k 10,000 shares | +5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.